Restoring Biological Harmony for Patients with Debilitating Disease
We are harnessing the power of microRNA science to develop therapies that normalize biological pathways and counterbalance disease.
Learn More
DEVELOPMENT PROGRAMS
Our pipeline is focused on serious diseases of high unmet need where the latest discoveries in microRNA biology are challenging traditional drug development paradigms and creating opportunities for novel therapeutic approaches.
Recent Press Releases
- miRagen to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
- miRagen, Investigators from Goethe University and University Hospital Frankfurt and Servier Publish MRG-110 Phase 1 Pharmacodynamic Biomarker Data in Nucleic Acid Therapeutics
- Cobomarsen Receives Orphan Drug Designation From the U.S. FDA for the Treatment of T-cell Lymphoma
- miRagen to Report Second Quarter 2020 Financial Results on August 5, 2020
- miRagen Regains Compliance With Nasdaq Listing Requirements